Parkinson's disease (PD) is a debilitating, progressive and costly neurodegenerative disease that affects over one million people annually in the US. 1 The four cardinal features of PD are well recognised, namely: tremor at rest, rigidity, bradykinesia and postural instability. Additionally, individuals with PD commonly develop non-motor symptoms such as autonomic dysfunction (orthostatic hypotension, and bowel and bladder dysfunction), neuropsychiatric symptoms (depression, anxiety, cognitive impairment and psychosis), sensory symptoms and sleep disturbances. In fact, patients with PD report an average of nearly 8 non-motor symptoms, with the frequency of such symptoms increasing with disease duration and severity. 2 Furthermore, as patients age, they are subject to other chronic medical comorbidities, 3 contributing to significant healthcare costs,4 hospitalisations andvisits to emergency departments. 5 As PD advances, non-motor symptoms, motor fluctuations and falls become more prominent and quality of life deteriorates. Advanced PD is commonly defined by clinicians as stage 4 and 5 on the Hoehn and Yahr scale. 6 As the disease progresses there is an emergence of a symptom constellation that may be non-responsive to levodopa which includes postural instability and falls, speech and swallowing difficulties, and other non-motor symptoms. 7 As PD advances, so too do polypharmacy, 8 emergency room visits, and hospitalisation rates. 9 Older age, increasing functional impairment, dementia, and hallucinations each independently predict institutionalization, with hallucinations being the strongest -and potentially, most treatable -risk factor. 10, 11 Institutionalised PD patients have greater mortality when compared to age-and disease duration-matched community-dwelling patients. 12, 13 Institutionalisation also distances patients from neurological expertise, and causes complex loss and grief for the caregiver. 14, 15 It is for all of these reasons that interventions to delay or prevent institutionalisation are desperately needed.
The role of the main caregiver, usually a family member, is crucial in the care of patients with PD. This responsibility becomes progressively more important with disease progression, with caregivers increasingly shouldering the burden for medication administration, disease management and physical and emotional support. 16 Published literature in PD points to an association between disease severity and caregiver strain, wherein the presence of visual hallucinations, cognitive impairment and depression in the patient significantly increase their caregiver's strain. [17] [18] [19] Caregiver strain affects not only the caregiver's own quality of life but also their perceived health status; although this relationship has been demonstrated to worsen with increasing PD severity of the patient, individuals with advanced PD are severely underrepresented in such studies. 20 Currently, the majority of research is focused on mild or moderate PD, and little is known about advanced PD patients. This is due, in large part, to these precise patients' disease severity and functional limitations impairing their access to clinical care. When clinical access is lost, so too is the opportunity to participate in research that would shed light on this stage of disease. Best practices for the treatment of advanced PD are understudied, and just as we have only begun to explore the impact of advanced disease on patients, this remains to be explored in their caregivers, as well. 20 We need to develop models that provide continuity of care -and as an extension, continuity of research opportunities -to patients with advanced PD. Telemedicine holds great promise for reaching beyond the clinic walls, though logistics may still prove a challenge for the most advanced PD patients. 21 Outside of neurology, another well-studied model is home-based care. Home visit models in various forms have flourished as a means of maintaining or improving the quality of care for complex elderly patients while reducing healthcare costs. 22 The majority of successful models have been interdisciplinary, incorporating nursing and social work care coordination in primary and specialty care. [22] [23] [24] Although home visits have been published in several other chronic diseases, in the case of PD it is still a relatively unexplored phenomenon. 25, 26 One such interdisciplinary home visit programme for PD and other associated disorders was described in the literature. 27 This programme lacked the involvement of a neurologist, however, and described neither the patients or volume served, Medicine. This novel programme, incorporating neurologic, social work, and nursing disciplines, aims to deliver evidence-based patient-and family-centered care to homebound patients with advanced PD, while prospectively studying patient-and caregiver-centered outcomes. Data are forthcoming, and a thorough investigation into the healthcare systemlevel cost-effectiveness will be crucial to future implementation and dissemination of such a model at other centers.
Health services research has brought to our attention the urgent need to foster early access to care for PD, both in the US and abroad. 29 The attendant imperative, then, is to preserve that hard-fought access to care, particularly when patients and caregivers need our expertise, counseling, and compassion the most. q
